Community post

There is currently no working treatment for recurring bacterial vaginosis (BV). Christine Landlinger (PhagoMed Biopharma GmbH) and colleagues published a new preprint in medRxiv showing that their engineered phage endolysin candidate eliminates Gardnerella in bacterial vaginosis without damaging the healthy vaginal microbiome. This is great news and paves the way for development of this lysin (which came from a prophage) as a vaginal suppository for BV.